Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).
John Smyth, MD, of the University of Edinburgh, discusses oncology from an international point of view.
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.
Christian Carrie, MD, of Centre Léon Bérard, and Celestia S. Higano, MD, of the University of Washington, discuss short hormonal therapy and radiotherapy as salvage treatment for relapse after radical prostatectomy (Abstract 5006).
Clifford A. Hudis, MD, and Maura N. Dickler, MD, of Memorial Sloan Kettering Cancer Center, discuss adding bevacizumab to letrozole as a first-line endocrine therapy for treatment of hormone receptor–positive advanced breast cancer (Abstract 501).
James O. Armitage, MD, of the University of Nebraska Medical Center, and Sagar Lonial, MD, of Emory University School of Medicine, discuss results from two important studies that tested lenalidomide/dexamethasone with or without elotuzumab and daratumumab monotherapy (Abstracts 8508 and LBA8512).
